Company IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.44 USD -1.88% Intraday chart for IGM Biosciences, Inc. -0.10% +25.63%

Business Summary

IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The Company has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.

Number of employees: 224

Sales per Business

USD in Million2022Weight2023Weight Delta
Engineered Immunoglobulin M Antibodies
100.0 %
1 100.0 % 2 100.0 % +99.25%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 2 100.0 % +99.25%

Managers

Managers TitleAgeSince
Chief Executive Officer 72 03-01-31
Director of Finance/CFO 49 18-12-31
Chief Operating Officer - 20-12-31
Chief Tech/Sci/R&D Officer 65 21-07-28
Chief Tech/Sci/R&D Officer 71 09-12-31
General Counsel - 20-12-31
Corporate Officer/Principal - 17-12-31
Corporate Officer/Principal 52 21-04-11
Comptroller/Controller/Auditor 48 22-02-28
General Counsel - 20-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 55 21-01-25
Director/Board Member 71 19-01-30
Chief Executive Officer 72 03-01-31
Director/Board Member 45 19-06-30
Director/Board Member 66 18-08-14
Director/Board Member 55 18-07-31
Director/Board Member 43 18-07-31
Director/Board Member 71 18-07-31
Director/Board Member 49 23-10-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 25,500,383 0 0 36.48 %
Stock B 1 33,286,205 21,447,677 ( 64.43 %) 0

Shareholders

NameEquities%Valuation
Topsøe Holding A/S
31.65 %
10,410,856 31.65 % 131 M $
Baker Bros. Advisors LP
11.22 %
3,691,011 11.22 % 47 M $
T. Rowe Price Associates, Inc. (Investment Management)
10.35 %
3,403,714 10.35 % 43 M $
T. Rowe Price International Ltd.
9.911 %
3,260,022 9.911 % 41 M $
Artal Group SA
9.426 %
3,100,422 9.426 % 39 M $
Redmile Group LLC
9.391 %
3,089,062 9.391 % 39 M $
Redmile Group LLC
9.034 %
2,971,542 9.034 % 38 M $
Fidelity Management & Research Co. LLC
5.164 %
1,698,506 5.164 % 21 M $
Goldman Sachs Asset Management LP
3.163 %
1,040,509 3.163 % 13 M $
RA Capital Management LP
2.850 %
937,500 2.850 % 12 M $
NameEquities%Valuation
Baker Bros. Advisors LP
35.11 %
10,720,924 35.11 % 135 M $
Redmile Group LLC
23.58 %
7,199,325 23.58 % 91 M $
Topsøe Holding A/S
16.52 %
5,044,295 16.52 % 64 M $

Company contact information

IGM Biosciences, Inc.

325 East Middlefield Road

94043, Mountain View

+650 965 7873

http://www.igmbio.com
address IGM Biosciences, Inc.(IGMS)